Saltar al contenido
Merck
Todas las fotos(1)

Documentos

SML1573

Sigma-Aldrich

Tolrestat

≥98% (HPLC)

Sinónimos:

AY-27773, CID 53359, N-[[5 -(Trifluoromethyl)-6-methoxy-lnaphthalenyl]thioxomethyl]-N-methylglycine, N-[[6-Methoxy-5-(trifluoromethyl)-1-naphthalenyl]thioxomethyl]-N-methyl-glycine, Tolrestatin

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C16H14F3NO3S
Número de CAS:
82964-04-3
Peso molecular:
357.35
UNSPSC Code:
12352200
NACRES:
NA.77

Quality Level

100

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 20 mg/mL, clear

storage temp.

2-8°C

InChI

1S/C16H14F3NO3S/c1-20(8-13(21)22)15(24)11-5-3-4-10-9(11)6-7-12(23-2)14(10)16(17,18)19/h3-7H,8H2,1-2H3,(H,21,22)

InChI key

LUBHDINQXIHVLS-UHFFFAOYSA-N

Biochem/physiol Actions

Tolrestat is an orally active and potent aldose reductase inhibitor. Studies have also shown that it reduces RBC (red blood cells) sorbitol levels in rats.
Tolrestat is considered to be effective in treating the consequences of diabetes including neuropathy, nephropathy, retinopathy and esophageal motility and vibration perception. Tolrestat is also believed to have lesser or no toxic effects.

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Effect of Tolrestat on oesophageal transit time and cholecystic motility in type 2 diabetic patients with asymptomatic diabetic neuropathy.
Fabiani F, et al.
Diabete & Metabolisme, 21(5), 360-364 (1995)
Principles of diabetes mellitus (2010)
Felicia D'Andrea et al.
Journal of enzyme inhibition and medicinal chemistry, 35(1), 1194-1205 (2020-05-13)
Aldose reductase is a key enzyme in the development of long term diabetic complications and its inhibition represents a viable therapeutic solution for people affected by these pathologies. Therefore, the search for effective aldose reductase inhibitors is a timely and
Susanna Nencetti et al.
Bioorganic & medicinal chemistry, 25(12), 3068-3076 (2017-04-11)
Aldose reductase (ALR2), a NADPH-dependent reductase, is the first and rate-limiting enzyme of the polyol pathway of glucose metabolism and is implicated in the pathogenesis of secondary diabetic complications. In the last decades, this enzyme has been targeted for inhibition

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico